In studies of ovarian cancer, three PARP1 inhibitors, olaparib [92], niraparib [93], and rucaparib [94] exploit synthetic lethality in platinum-sensitive, relapsed serous ovarian cancer. This evidence concerns the gene PARP1 and ovarian carcinoma.